

PRODUCT SPECIFICATIONS

Product Components




Test cassette



Extraction buffer






Extraction tube



Swab

Operation procedure



Performance

Reagents		PCR		Total
		Positive	Negative	
Wondfo 2019-nCoV Antigen Test (Lateral Flow Method)	Positive	208	1	209
	Negative	4	361	365
Total		212	362	574

Sensitivity: 98.11% (95%CI: 95.24%~99.48%)  
Specificity: 99.72% (95%CI: 98.47%~99.99%)  
Total agreement: 99.13% (95%CI: 97.98%~99.72%)

Order information

Catalog No.	Product Name	Packing Size	Sample Type	Storage Condition	Shelf Life	Qualification
W196	2019-nCoV Antigen Test (Lateral Flow Method)	20T	Nasopharyngeal swab or oropharyngeal swab	2~30 °C	12 months	CE

WONDFO BIOTECH  
WeAreWorkingForYourHealth

Wondfo®

Guangzhou Wondfo Biotech Co., Ltd.  
Add: No. 8 Lizhishan Road, Science City, Luogang District, 510663, Guangzhou, P.R. China  
Tel: +86-20-32296083 Fax: +86-20-32296063  
E-mail: sales@wondfo.com.cn Websites: en.wondfo.com.cn  
Wondfo reserves all rights. All contents of this brochure are copyrighted by Wondfo.



Wondfo®

WONDFO  
2019-nCoV  
ANTIGEN  
TEST

Speed Up the COVID-19 Control !



# WONDFO 2019-nCoV ANTIGEN TEST



Direct detection  
of the virus



Instant results  
within 15mins



Easy to use, no  
equipment required



Room temperature  
storage (2~30°C)




Non-invasive sampling  
(sample type: nasopharyngeal  
or oropharyngeal swab)



Early detection of COVID-19  
(WHO recommends the testing period  
is from 3 days before to 5-7 days  
after symptoms onset)

## CURRENT DIAGNOSTIC METHODS FOR COVID-19



### Antigen test

Detect the antigen of the virus, indicating the active viral infection.

### RT-PCR

Detect the RNA of virus, indicating the active viral infection.

### Antibody test


Detect the antibody generated by immune response after viral infection, indicating the active or past viral infection.

## WHEN TO USE ANTIGEN TEST?

### Releasing profile

Levels of 2019-nCoV virus and antibodies after infection

\*For illustrative purpose only



\* Incubation Period: 1-14 days, mostly 3-7 days  
\* Antibody Window Period: 5-10 days after onset of symptoms

\* The minimum detectable limit varies with methodology and sensitivity of test  
\* IgG antibody test can be referred as one of discharge criteria for recovering COVID-19 patients


## ANTIGEN TEST ADVANTAGES

### Antigen test OVER RT-PCR

- Short turn-around time  
(Antigen test: 20mins vs. RT-PCR: 2hours)
- Inexpensive cost, no equipment required and simple operation make antigen test suitable for point-of-care (POC) setting usage.

### Antigen test OVER Antibody test

- Detect the virus directly, allowing the early detection of COVID-19
- Non-invasive sampling  
(sampling type: blood vs. swab)




## ANTIGEN TEST APPLICATION

Similar to RT-PCR, the detection of antigen indicates the active infection. Under the circumstance that the area(s) still undergo widespread community transmission with limited RT-PCR resources, antigen can be used for aiding in the diagnosis of COVID-19 suspect patients.


\* American CDC also recommends to use rapid antigen tests for screening testing in high-risk congregate settings where the immediate result is required.

### Result interpretation



### POSITIVE

The patient is undergo active 2019-nCoV infection. Further isolation is required.




### NEGATIVE

The patient should be further evaluated by RT-PCR, especially if the result of the antigen test is inconsistent with the clinical context.

## ANTIGEN TEST OFFICIAL GUIDELINES



Antigen-detection in the diagnosis of novel coronavirus (2019-nCoV) infection using rapid immunoassays



NPV- negative predictive value PPV- positive predictive value  
\*The value for NPV and PPV is decided based on products performance and disease prevalence in applied scenarios.

### Other antigen test related guidelines

- Interim Guidance for Rapid Antigen Testing for 2019-nCoV, American CDC (8-16-20)
- Considerations for Use of 2019-nCoV Antigen Testing in Nursing Homes, American CDC (8-27-20)
- Antigen-Detection in the Diagnosis of 2019-nCoV Infection Using Rapid Immunoassays, WHO (9-11-20)
- Considerations for Implementation of 2019-nCoV Rapid Antigen Testing, APHL (9-2-20)